- Home
- DETX vs CYCN Comparison
DETX vs CYCN Comparison
Compare DETX & CYCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DETX | CYCN |
|---|---|---|
| Founded | N/A | 2018 |
| Country | United States | United States |
| Employees | 27 | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.5M | 16.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | DETX | CYCN |
|---|---|---|
| Price | $3.27 | $3.37 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 8.2K | ★ 19.0K |
| Earning Date | N/A | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.22 | $1.03 |
| 52 Week High | $4.25 | $8.48 |
Technical Indicators
Market Signals| Indicator | DETX | CYCN |
|---|---|---|
| Relative Strength Index (RSI) | 25.20 | 53.50 |
| Support Level | N/A | $2.93 |
| Resistance Level | $3.41 | $3.97 |
| Average True Range (ATR) | 0.17 | 0.23 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 6.43 | 33.33 |
Price Performance
Historical ComparisonAbout DETX Liberty Defense Holdings Ltd. Common Shares
Liberty Defense Holdings Ltd is engaged in the development and commercialization of security detection technologies such as airports, stadiums, schools, and more. The company's Hexwave product utilizes millimeter wave technology and Advanced 3D imaging to detect concealed threats. In addition to HEXWAVE, the company has licensed High-Definition Advanced Imaging Technology (HD-AIT) for body and shoe scanning. The Company operates through three distinct segments: Corporate, HEXWAVE, and Contract. The company generates the majority of its revenue from the Contract segment. Geographically, the company generates the majority of its revenue from the United States.
About CYCN Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. The company focuses on enabling the full therapeutic potential of next-generation sGC stimulators and neuropsychiatric diseases. Its pipeline products include Olinciguat, Praliciguat, and others.